Pub Date : 2024-01-17DOI: 10.1016/j.bcmd.2024.102826
Sangsang Wang , Diao Yu , Junwu Zhang
{"title":"Regarding γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity","authors":"Sangsang Wang , Diao Yu , Junwu Zhang","doi":"10.1016/j.bcmd.2024.102826","DOIUrl":"10.1016/j.bcmd.2024.102826","url":null,"abstract":"","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139499238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-12DOI: 10.1016/j.bcmd.2024.102825
Lucy Z. Kornblith , Bindhya Sadhanandhan , Sreepriya Arun , Rebecca Long , Alicia J. Johnson , Jamie Noll , C.N. Ramchand , John K. Olynyk , David H. Farrell
{"title":"Regarding γ′ fibrinogen levels as a biomarker of COVID-19 respiratory disease severity","authors":"Lucy Z. Kornblith , Bindhya Sadhanandhan , Sreepriya Arun , Rebecca Long , Alicia J. Johnson , Jamie Noll , C.N. Ramchand , John K. Olynyk , David H. Farrell","doi":"10.1016/j.bcmd.2024.102825","DOIUrl":"10.1016/j.bcmd.2024.102825","url":null,"abstract":"","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-04DOI: 10.1016/j.bcmd.2023.102822
Brígida Santos , Catarina Ginete , Elisângela Gonçalves , Mariana Delgadinho , Armandina Miranda , Paula Faustino , Ana Paula Arez , Miguel Brito
Background
Sickle Cell Anemia (SCA) is a monogenic disease, although its severity and response to treatment are very heterogeneous.
Objectives
This study aims to characterize a cohort of Angolan children with SCA and evaluate their response to hydroxyurea (HU) treatment and the potential side effects and toxicity.
Methods
The study enrolled 215 patients between 3 and 12 years old before and after the administration of HU, at a fix dose of 20 mg/kg/day for 12 months.
Results
A total of 157 patients started HU medication and 141 of them completed the 12-month treatment. After initiating HU treatment, the frequency of clinical events decreased (transfusions 53.4 %, hospitalizations 47.1 %). The response to HU medication varied among patients, with some experiencing an increase in fetal hemoglobin (HbF) of <5 %. The mean increase in HbF was 11.9 %, ranging from 1.8 % to 31 %. Responders to HU treatment were 57 %, inadequate responders 38.7 % and non-adherent 4.2 %. No clinical side effects related to HU were reported. Hematological toxicities were transient and reversible. Children naïve to HU and with lower HbF reported higher number of hospitalizations caused by malaria infection. During HU treatment, the frequency of malaria episodes did not appear to be affected by HbF levels.
Conclusions
the present study provided a valuable contribution to the understanding of the clinical and laboratory profiles of Angolan children with SCA. These findings support the evidence that the implementation of prophylactic measures and treatment with HU is associated with increased survival in children with SCA.
背景镰状细胞性贫血(SCA)是一种单基因疾病,但其严重程度和对治疗的反应各不相同。结果共有157名患者开始接受羟基脲治疗,其中141人完成了为期12个月的治疗。开始使用 HU 治疗后,临床事件的发生率有所下降(输血率为 53.4%,住院率为 47.1%)。不同患者对 HU 药物的反应各不相同,有些患者的胎儿血红蛋白(HbF)增加了 5%。HbF 的平均增幅为 11.9%,从 1.8% 到 31% 不等。对 HU 治疗有反应的占 57%,反应不充分的占 38.7%,未坚持治疗的占 4.2%。没有与HU相关的临床副作用报告。血液学毒性是短暂和可逆的。初用 HU 和 HbF 较低的儿童因感染疟疾而住院的次数较多。本研究为了解安哥拉 SCA 儿童的临床和实验室概况做出了宝贵贡献。这些研究结果支持这样的证据,即实施预防措施和使用HU治疗与提高SCA患儿的存活率有关。
{"title":"Characterization of a cohort of Angolan children with sickle cell anemia treated with hydroxyurea","authors":"Brígida Santos , Catarina Ginete , Elisângela Gonçalves , Mariana Delgadinho , Armandina Miranda , Paula Faustino , Ana Paula Arez , Miguel Brito","doi":"10.1016/j.bcmd.2023.102822","DOIUrl":"10.1016/j.bcmd.2023.102822","url":null,"abstract":"<div><h3>Background</h3><p>Sickle Cell Anemia (SCA) is a monogenic disease, although its severity and response to treatment are very heterogeneous.</p></div><div><h3>Objectives</h3><p>This study aims to characterize a cohort of Angolan children with SCA and evaluate their response to hydroxyurea (HU) treatment and the potential side effects and toxicity.</p></div><div><h3>Methods</h3><p>The study enrolled 215 patients between 3 and 12 years old before and after the administration of HU, at a fix dose of 20 mg/kg/day for 12 months.</p></div><div><h3>Results</h3><p>A total of 157 patients started HU medication and 141 of them completed the 12-month treatment. After initiating HU treatment, the frequency of clinical events decreased (transfusions 53.4 %, hospitalizations 47.1 %). The response to HU medication varied among patients, with some experiencing an increase in fetal hemoglobin (HbF) of <5 %. The mean increase in HbF was 11.9 %, ranging from 1.8 % to 31 %. Responders to HU treatment were 57 %, inadequate responders 38.7 % and non-adherent 4.2 %. No clinical side effects related to HU were reported. Hematological toxicities were transient and reversible. Children naïve to HU and with lower HbF reported higher number of hospitalizations caused by malaria infection. During HU treatment, the frequency of malaria episodes did not appear to be affected by HbF levels.</p></div><div><h3>Conclusions</h3><p>the present study provided a valuable contribution to the understanding of the clinical and laboratory profiles of Angolan children with SCA. These findings support the evidence that the implementation of prophylactic measures and treatment with HU is associated with increased survival in children with SCA.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1079979623000992/pdfft?md5=6ac4fc1b23206523b69ea849bc5368bf&pid=1-s2.0-S1079979623000992-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139094036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-04DOI: 10.1016/j.bcmd.2024.102823
Usman Ali Shams , Isma Javed , Muhammad Fizan , Aqib Raza Shah , Ghulam Mustafa , Muhammad Zubair , Yehia Massoud , Muhammad Qasim Mehmood , Muhammad Asif Naveed
Peripheral blood smear examination is one of the basic steps in the evaluation of different blood cells. It is a confirmatory step after an automated complete blood count analysis. Manual microscopy is time-consuming and requires professional laboratory expertise. Therefore, the turn-around time for peripheral smear in a health care center is approximately 3–4 hours. To avoid the traditional method of manual counting under the microscope a computerized automation of peripheral blood smear examination has been adopted, which is a challenging task in medical diagnostics. In recent times, deep learning techniques have overcome the challenges associated with human microscopic evaluation of peripheral smears and this has led to reduced cost and precise diagnosis. However, their application can be significantly improved by the availability of annotated datasets. This study presents a large customized annotated blood cell dataset (named the Bio-Net dataset from healthy individuals) and blood cell detection and counting in the peripheral blood smear images. A mini-version of the dataset for specialized WBC-based image processing tasks is also equipped to classify the healthy and mature WBCs in their respective classes. An object detection algorithm called You Only Look Once (YOLO) with a refashion disposition has been trained on the novel dataset to automatically detect and classify blood cells into RBCs, WBCs, and platelets and compare the results with other publicly available datasets to highlight the versatility. In short the introduction of the Bio-Net dataset and AI-powered detection and counting offers a significant potential for advancement in biomedical research for analyzing and understanding biological data.
{"title":"Bio-net dataset: AI-based diagnostic solutions using peripheral blood smear images","authors":"Usman Ali Shams , Isma Javed , Muhammad Fizan , Aqib Raza Shah , Ghulam Mustafa , Muhammad Zubair , Yehia Massoud , Muhammad Qasim Mehmood , Muhammad Asif Naveed","doi":"10.1016/j.bcmd.2024.102823","DOIUrl":"10.1016/j.bcmd.2024.102823","url":null,"abstract":"<div><p><span>Peripheral blood smear examination is one of the basic steps in the evaluation of different </span>blood cells<span>. It is a confirmatory step after an automated complete blood count<span> analysis. Manual microscopy is time-consuming and requires professional laboratory expertise. Therefore, the turn-around time for peripheral smear in a health care<span> center is approximately 3–4 hours. To avoid the traditional method of manual counting under the microscope a computerized automation of peripheral blood smear examination has been adopted, which is a challenging task in medical diagnostics. In recent times, deep learning techniques have overcome the challenges associated with human microscopic evaluation of peripheral smears and this has led to reduced cost and precise diagnosis. However, their application can be significantly improved by the availability of annotated datasets. This study presents a large customized annotated blood cell dataset (named the Bio-Net dataset from healthy individuals) and blood cell detection and counting in the peripheral blood smear images. A mini-version of the dataset for specialized WBC-based image processing tasks is also equipped to classify the healthy and mature WBCs in their respective classes. An object detection algorithm called You Only Look Once (YOLO) with a refashion disposition has been trained on the novel dataset to automatically detect and classify blood cells into RBCs, WBCs, and platelets and compare the results with other publicly available datasets to highlight the versatility. In short the introduction of the Bio-Net dataset and AI-powered detection and counting offers a significant potential for advancement in biomedical research for analyzing and understanding biological data.</span></span></span></p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139396173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dyslipidemia is frequently observed in polycystic ovarian syndrome (PCOS). Changes in plasma lipid levels potentially alter erythrocyte membrane lipid composition due to lack of inbuilt lipid synthesis machinery. Therefore, development of morphologically altered erythrocytes in PCOS patients with dyslipidemia is expected. However, this has not been established so far. So, we took this opportunity to explore the morphological alterations among dyslipidemic PCO women. We recruited thirty-five dyslipidemic PCOS women (satisfying Rotterdam criteria, without medication) and twenty-five age-matched healthy controls. Scanning electron microscopy revealed a significant increase in the number of stomatocytes, acanthocytes, and echinocytes in the PCO group. PCO group showed a considerable decrease in plasma antioxidant levels. Elevated lipid peroxidation, protein carbonylation, and decreased free thiol group in erythrocyte membrane in PCOS suggest oxidative degradation of the erythrocyte membrane. Elevated intracellular ROS levels, increased methemoglobin formation, and a decrease in NADPH methemoglobin reductase in PCOS also indicate altered physicochemical property of hemoglobin due to oxidative overload. Additionally, these patients exhibit a rise in erythrocyte membrane cholesterol and triglyceride, which promotes the membrane to become less fluidic and less fragile. Thus, these results corroborate a potential role in altering erythrocyte morphology among dyslipidemic PCO women.
{"title":"Unmasking the morphological alteration of erythrocytes among women suffering from PCOS","authors":"Sutithi Dey , Ipsita Chakraborty , Payel Biswas , Ayantika Paul , Pratip Chakraborty , Rajen Haldar","doi":"10.1016/j.bcmd.2023.102821","DOIUrl":"10.1016/j.bcmd.2023.102821","url":null,"abstract":"<div><p><span><span><span>Dyslipidemia<span> is frequently observed in polycystic ovarian syndrome (PCOS). Changes in plasma </span></span>lipid levels<span><span> potentially alter erythrocyte membrane<span> lipid composition due to lack of inbuilt </span></span>lipid synthesis<span><span> machinery. Therefore, development of morphologically altered erythrocytes in PCOS patients with dyslipidemia is expected. However, this has not been established so far. So, we took this opportunity to explore the morphological alterations among dyslipidemic PCO women. We recruited thirty-five dyslipidemic PCOS women (satisfying Rotterdam criteria, without medication) and twenty-five age-matched healthy controls. Scanning electron microscopy revealed a significant increase in the number of stomatocytes, </span>acanthocytes, and </span></span></span>echinocytes<span> in the PCO group. PCO group showed a considerable decrease in plasma antioxidant levels. Elevated lipid peroxidation, </span></span>protein carbonylation<span><span><span><span>, and decreased free thiol group in erythrocyte membrane in PCOS suggest </span>oxidative degradation of the erythrocyte membrane. Elevated intracellular </span>ROS<span> levels, increased methemoglobin formation, and a decrease in NADPH methemoglobin reductase in PCOS also indicate altered physicochemical property of hemoglobin due to oxidative overload. Additionally, these patients exhibit a rise in erythrocyte membrane cholesterol and </span></span>triglyceride<span>, which promotes the membrane to become less fluidic and less fragile. Thus, these results corroborate a potential role in altering erythrocyte morphology among dyslipidemic PCO women.</span></span></p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139094278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with post-transplant cyclophosphamide (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34+ cell dose in grafts has not been fully elucidated.
Objective
We aimed to explore the impact of CD34+ cell dose on outcomes after haplo-PBSCT with PTCy.
Study Design
We retrospectively investigated 111 consecutive patients who underwent haplo-PBSCT with PTCy or HLA-matched PBSCT from related donors.
Results
There were no statistically significant differences in 3-year overall survival (p = 0.559) or progression-free survival (p = 0.974) between haplo-PBSCT and matched PBSCT. Delayed neutrophil engraftment and a lower incidence of graft-versus-host disease were observed in haplo-PBSCT. The median dose of CD34+ cells was 4.9 × 106 /kg in 57 haplo-PBSCT and 4.5 × 106 /kg in 54 matched PBSCTs. Importantly, patients who underwent haplo-PBSCT with the administration of CD34+ cell at a dose of ≥4.0 × 106 /kg significantly had improved OS (p = 0.015) and decreased incidence of disease relapse (p = 0.001) without increasing incidence of GVHD.
Conclusion
Our data suggest that a higher dose of CD34+ cells in haplo-PBSCT with PTCy positively impacts the outcomes without an increase of GVHD.
{"title":"Impact of CD34 positive cell dose in donor graft on the outcomes after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide – A retrospective single-center study with a Japanese cohort","authors":"Yumiko Maruyama , Hidekazu Nishikii , Naoki Kurita , Tatsuhiro Sakamoto , Keiichiro Hattori , Yasuhito Suehara , Yasuhisa Yokoyama , Takayasu Kato , Naoshi Obara , Mamiko Sakata-Yanagimoto , Shigeru Chiba","doi":"10.1016/j.bcmd.2023.102820","DOIUrl":"10.1016/j.bcmd.2023.102820","url":null,"abstract":"<div><h3>Background</h3><p><span>Haploidentical peripheral blood stem cell transplantation<span> (haplo-PBSCT) with post-transplant cyclophosphamide<span> (PTCy) is an important therapeutic option for patients lacking an HLA-matched donor. However, the significance of CD34</span></span></span><sup>+</sup> cell dose in grafts has not been fully elucidated.</p></div><div><h3>Objective</h3><p>We aimed to explore the impact of CD34<sup>+</sup> cell dose on outcomes after haplo-PBSCT with PTCy.</p></div><div><h3>Study Design</h3><p>We retrospectively investigated 111 consecutive patients who underwent haplo-PBSCT with PTCy or HLA-matched PBSCT from related donors.</p></div><div><h3>Results</h3><p>There were no statistically significant differences in 3-year overall survival (<em>p</em> = 0.559) or progression-free survival (<em>p</em><span> = 0.974) between haplo-PBSCT and matched PBSCT. Delayed neutrophil<span> engraftment and a lower incidence of graft-versus-host disease were observed in haplo-PBSCT. The median dose of CD34</span></span><sup>+</sup> cells was 4.9 × 10<sup>6</sup> /kg in 57 haplo-PBSCT and 4.5 × 10<sup>6</sup> /kg in 54 matched PBSCTs. Importantly, patients who underwent haplo-PBSCT with the administration of CD34<sup>+</sup> cell at a dose of ≥4.0 × 10<sup>6</sup> /kg significantly had improved OS (<em>p</em> = 0.015) and decreased incidence of disease relapse (<em>p</em> = 0.001) without increasing incidence of GVHD.</p></div><div><h3>Conclusion</h3><p>Our data suggest that a higher dose of CD34<sup>+</sup> cells in haplo-PBSCT with PTCy positively impacts the outcomes without an increase of GVHD.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139065475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-07DOI: 10.1016/j.bcmd.2023.102819
Marshall A. Lichtman , Josef T. Prchal
{"title":"Measurement of red cell, plasma and blood volume: Essential components of diagnostic and research studies of oxygen transport","authors":"Marshall A. Lichtman , Josef T. Prchal","doi":"10.1016/j.bcmd.2023.102819","DOIUrl":"10.1016/j.bcmd.2023.102819","url":null,"abstract":"","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138555924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-05DOI: 10.1016/j.bcmd.2023.102801
Marshall A. Lichtman
Several syndromes affecting the red cell that mimic those induced by germline mutations may result from a somatic mutation that accompanies a myeloid malignancy. These syndromes are most notable in cases of myelodysplastic syndrome, but they are not limited to any one category of myeloid neoplasm. Their occurrence in males exceed the male predominance that is evident in myeloid neoplasms. The syndromes include disorders of globin chain synthesis (α- and β-thalassemia), heme synthesis (erythropoietic porphyria and erythropoietic uroporphyria), red cell membrane structure (elliptocytosis and spherocytosis), red cell enzyme activity (pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase deficiency) and lowered expression of red cell ABO blood group antigens. This historical review describes the path to uncovering these acquired syndromes and their causal somatic mutations, where known. These syndromes often go unrecognized because of the dominant concern of the primary neoplasm. They may add to the healthcare needs of the patient.
{"title":"Clonal hematopoiesis and acquired genetic abnormalities of the red cell: An historical review","authors":"Marshall A. Lichtman","doi":"10.1016/j.bcmd.2023.102801","DOIUrl":"10.1016/j.bcmd.2023.102801","url":null,"abstract":"<div><p>Several syndromes affecting the red cell that mimic those induced by germline mutations may result from a somatic mutation that accompanies a myeloid malignancy. These syndromes are most notable in cases of myelodysplastic syndrome, but they are not limited to any one category of myeloid neoplasm. Their occurrence in males exceed the male predominance that is evident in myeloid neoplasms. The syndromes include disorders of globin chain synthesis (α- and β-thalassemia), heme synthesis (erythropoietic porphyria and erythropoietic uroporphyria), red cell membrane structure (elliptocytosis and spherocytosis), red cell enzyme activity (pyruvate kinase deficiency, glucose-6-phosphate dehydrogenase deficiency) and lowered expression of red cell ABO blood group antigens. This historical review describes the path to uncovering these acquired syndromes and their causal somatic mutations, where known. These syndromes often go unrecognized because of the dominant concern of the primary neoplasm. They may add to the healthcare needs of the patient.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89716868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-02DOI: 10.1016/j.bcmd.2023.102800
Luis E.F. Almeida, Meghann L. Smith, Sayuri Kamimura, Sebastian Vogel, Zenaide M.N. Quezado
Red blood cells (RBC) from patients with sickle cell disease (SCD) have elevated calcium levels at baseline, which are further elevated upon deoxygenation. Here we examined baseline calcium levels and calcium flux in RBCs from a mouse model of SCD mice. We found that akin to humans with SCD, sickle (HbSS) Townes mice, have higher baseline levels and increased calcium flux in RBCs compared to control (HbAA) animals. As HbSS mice, unlike humans with SCD, have high mean corpuscular volume compared with HbAA, we highlight the importance of adjusting biochemical results to number of RBCs rather than hematocrit during the analysis and interpretation of the results. Our findings add to the face validity of humanized sickle cell mice and support its use for studies of RBC calcium flux in SCD.
{"title":"Calcium flux alterations in erythrocytes from sickle cell mice: The relevance of mean corpuscular volume","authors":"Luis E.F. Almeida, Meghann L. Smith, Sayuri Kamimura, Sebastian Vogel, Zenaide M.N. Quezado","doi":"10.1016/j.bcmd.2023.102800","DOIUrl":"10.1016/j.bcmd.2023.102800","url":null,"abstract":"<div><p>Red blood cells (RBC) from patients with sickle cell disease (SCD) have elevated calcium levels at baseline, which are further elevated upon deoxygenation. Here we examined baseline calcium levels and calcium flux in RBCs from a mouse model of SCD mice. We found that akin to humans with SCD, sickle (HbSS) Townes mice, have higher baseline levels and increased calcium flux in RBCs compared to control (HbAA) animals. As HbSS mice, unlike humans with SCD, have high mean corpuscular volume compared with HbAA, we highlight the importance of adjusting biochemical results to number of RBCs rather than hematocrit during the analysis and interpretation of the results. Our findings add to the face validity of humanized sickle cell mice and support its use for studies of RBC calcium flux in SCD.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89716867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-10-09DOI: 10.1016/j.bcmd.2023.102799
Natália Sudan Parducci , Anali Del Milagro Bernabe Garnique , Keli Lima , Jorge Antonio Elias Godoy Carlos , Natasha Peixoto Fonseca , Lívia Bassani Lins de Miranda , Bruna Oliveira de Almeida , Eduardo Magalhães Rego , Fabiola Traina , João Agostinho Machado-Neto
Myeloproliferative neoplasms (MPN) are consolidated as a relevant group of diseases derived from the malfunction of the hematopoiesis process and have as a particular attribute the increased proliferation of myeloid lineage. Among these, chronic neutrophilic leukemia (CNL) is distinguished, caused by the T618I mutation of the CSF3R gene, a trait that generates ligand-independent receptor activation and downstream JAK2/STAT signaling. Previous studies reported that mutations in BCR::ABL1 and JAK2V617F increased the expression of the aurora kinase A (AURKA) and B (AURKB) in Ba/F3 cells and their pharmacological inhibition displays antineoplastic effects in human BCR::ABL1 and JAK2V617F positive cells. Delimiting the current scenario, aspects related to the AURKA and AURKB as a potential target in CSF3RT618I-driven models is little known. In the present study, the cellular and molecular effects of pharmacological inhibitors of aurora kinases, such as aurora A inhibitor I, AZD1152-HQPA, and reversine, were evaluated in Ba/F3 expressing the CSF3RT618I mutation. AZD1152-HQPA and reversine demonstrated antineoplastic potential, causing a decrease in cell viability, clonogenicity, and proliferative capacity. At molecular levels, all inhibitors reduced histone H3 phosphorylation, aurora A inhibitor I and reversine reduced STAT5 phosphorylation, and AZD1152-HQPA and reversine induced PARP1 cleavage and γH2AX expression. Reversine more efficiently modulated genes associated with cell cycle and apoptosis compared to other drugs. In summary, our findings shed new insights into the use of AURKB inhibitors in the context of CNL.
{"title":"Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3RT618I-driven cells","authors":"Natália Sudan Parducci , Anali Del Milagro Bernabe Garnique , Keli Lima , Jorge Antonio Elias Godoy Carlos , Natasha Peixoto Fonseca , Lívia Bassani Lins de Miranda , Bruna Oliveira de Almeida , Eduardo Magalhães Rego , Fabiola Traina , João Agostinho Machado-Neto","doi":"10.1016/j.bcmd.2023.102799","DOIUrl":"https://doi.org/10.1016/j.bcmd.2023.102799","url":null,"abstract":"<div><p><span>Myeloproliferative neoplasms<span><span> (MPN) are consolidated as a relevant group of diseases<span> derived from the malfunction of the hematopoiesis process and have as a particular attribute the increased proliferation of myeloid </span></span>lineage<span>. Among these, chronic neutrophilic leukemia (CNL) is distinguished, caused by the T618I mutation of the </span></span></span><em>CSF3R</em><span> gene, a trait that generates ligand-independent receptor activation and downstream JAK2/STAT signaling. Previous studies reported that mutations in BCR::ABL1 and JAK2</span><sup>V617F</sup><span> increased the expression of the aurora kinase A<span> (AURKA) and B (AURKB) in Ba/F3 cells and their pharmacological inhibition displays antineoplastic effects in human BCR::ABL1 and JAK2</span></span><sup>V617F</sup> positive cells. Delimiting the current scenario, aspects related to the AURKA and AURKB as a potential target in CSF3R<sup>T618I</sup><span>-driven models is little known. In the present study, the cellular and molecular effects of pharmacological inhibitors of aurora kinases, such as aurora A inhibitor I, AZD1152-HQPA, and reversine, were evaluated in Ba/F3 expressing the CSF3R</span><sup>T618I</sup><span><span><span><span><span> mutation. AZD1152-HQPA and reversine demonstrated antineoplastic potential, causing a decrease in cell viability, </span>clonogenicity, and proliferative capacity. At molecular levels, all inhibitors reduced </span>histone H3<span> phosphorylation, aurora A inhibitor I and reversine reduced STAT5 phosphorylation, and AZD1152-HQPA and reversine induced </span></span>PARP1<span> cleavage and γH2AX expression. Reversine more efficiently modulated genes associated with cell cycle and apoptosis compared to other </span></span>drugs. In summary, our findings shed new insights into the use of AURKB inhibitors in the context of CNL.</span></p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49821171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}